Hematology

Latest News

CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

April 3rd 2025

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

Targeting GPRC5D Holds Promise in Multiple Myeloma
Targeting GPRC5D Holds Promise in Multiple Myeloma

April 3rd 2025

Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
PROs Associated With Survival, AEs in Multiple Myeloma

April 3rd 2025

ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
ESA Treatment Improves OS in Lower-Risk MDS

March 28th 2025

ASH logo | images: ASH
Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

March 24th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

MM Top 5 Thumbnail
December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Maggie L. Shaw
Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.
A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com
December 19th 2024

Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease

Karen Jacobson-Sive
Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD
A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
MDS graphic | Image Credit: © Sviatlana-stock.adobe.com
December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD
Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
ICYMI: Highlights From IMS 2024
December 17th 2024

ICYMI: Highlights From IMS 2024

Maggie L. Shaw
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
MDS | Image Credit: © ibreakstock-stock.adobe.com
December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive
Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.
CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Matias Sanchez, MD
December 2nd 2024

Balancing Cutting-Edge Therapies With Cost in Multiple Myeloma Treatment

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.
New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com
November 29th 2024

Tattoos May Be Associated With Increased Risk of Rare NHLs

AJMC Contributor
Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.
Matias Sanchez, MD
November 29th 2024

Transforming Multiple Myeloma Care With Education and Advanced Therapies

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.
FDA Approval | image credit: gomixer - stock.adobe.com
November 26th 2024

FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

Kyle Munz
The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.
Guidelines | Image Credit: © momius-stock.adobe.com
November 26th 2024

NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma

Maggie L. Shaw
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Clinical trial results-Egor-stock.adobe.com.jpeg
November 26th 2024

Progression-Free Survival in Relapsed Multiple Myeloma Extended With Ixazomib, Data Show

Giuliana Grossi
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.
Big Data | Image Credit: © Friends Stock-stock.adobe.com
November 26th 2024

Real-World Data Confirm Ibrutinib's Role in Relapsed CLL

Gayle Turim Dickstein
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Don M. Benson, MD, PhD, James Cancer Hospital
November 22nd 2024

Balancing Life and Myeloma: A Patient-Centered Approach

Maggie L. Shaw
In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Elevating Value in Cancer Care With Innovations, Accessibility, Equity
November 21st 2024

Elevating Value in Cancer Care With Innovations, Accessibility, Equity

Cameron Santoro
Coverage from the IVBM Regional event in Denver, Colorado.
AML cells concept | image credit: sovova - stock.adobe.com
November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Don M. Benson, MD, PhD, James Cancer Hospital
November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

Maggie L. Shaw
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Genes - CrazyJuke - stock.adobe.com
November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

Kimberly Rath, PharmD
Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).
Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

Kimberly Rath, PharmD
Posttransplantation treatment with either tacrolimus or cyclosporine A results in favorable outcomes, but tacrolimus may be better at preventing severe graft-versus-host disease (GVHD), according to new study findings.
Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
November 2nd 2024

Patients With MDS Disagree With Physicians About Symptom Frequency

Jared Kaltwasser
Physicians also differed from caregivers when asked how many hours of caregiving patients required each week.
New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
Respiratory tract infections may occur in patients with CLL taking BTK inhibitors | image credit: Worldillustrator - stock.adobe.com
November 2nd 2024

Review Emphasizes Potential Infection Risks With BTK Inhibitors

Gayle Turim Dickstein
Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Surbhi Sidana, MD, MBBS
October 24th 2024

MRD: A Game Changer in Multiple Myeloma

Maggie L. Shaw
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease (MRD) status.
Ibrutinib molecule | image credit: molekuul.be - stock.adobe.com
October 23rd 2024

Understanding Ibrutinib Relapse in CLL: Immune Profiles of Responders vs Relapsing Patients

Kimberly Rath, PharmD
A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy.
Blood smear AML | image credit: Chansom Pantip - stock.adobe.com
October 20th 2024

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

AJMC Contributor
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Myeloid malignancy concept, blood cells floating | image credit: Eleni - stock.adobe.com
October 18th 2024

Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

Kimberly Rath, PharmD
A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML | image credit: Matthieu - stock.adobe.com
October 16th 2024

Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML

Jared Kaltwasser
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.
Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com
October 9th 2024

Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL

Jared Kaltwasser
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.
<12345678
...
25>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo